Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 159

Results For "Research"

2380 News Found

50%+ patients delay cataract surgeries in India: Survey
Public Health | June 28, 2022

50%+ patients delay cataract surgeries in India: Survey

73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries


Novartis commits US$ 250 million to the fight against NTDs and malaria
Public Health | June 24, 2022

Novartis commits US$ 250 million to the fight against NTDs and malaria

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.


Vividion Therapeutics names Aleksandra Rizo as President and Head of R&D
People | June 24, 2022

Vividion Therapeutics names Aleksandra Rizo as President and Head of R&D

Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.


Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine
News | June 24, 2022

Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine

An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.


CPC Scientific announces new California peptide API manufacturing facility
News | June 24, 2022

CPC Scientific announces new California peptide API manufacturing facility

The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity


Avni announces subscription model menstrual hygiene products
Healthcare | June 23, 2022

Avni announces subscription model menstrual hygiene products

The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users


Merck presents positive results from phase 1/2 study evaluating V116
News | June 22, 2022

Merck presents positive results from phase 1/2 study evaluating V116

V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019


AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza
News | June 22, 2022

AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza

LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)


Iktos and Zealand Pharma to develop AI technology for peptide drug design
Digitisation | June 22, 2022

Iktos and Zealand Pharma to develop AI technology for peptide drug design

Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design


Cortexyme announces preclinical data demonstrating efficacy of COR803 for Covid infections
News | June 22, 2022

Cortexyme announces preclinical data demonstrating efficacy of COR803 for Covid infections

COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.